Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial

Javier Cortes; Veronique Dieras; Jungsil Ro; Jerome Barriere; Thomas Bachelot; Sara Hurvitz; Emilie Le Rhun; Marc Espie; Sung-Bae Kim; Andreas Schneeweiss; Joo Hyuk Sohn; Jean-Marc Nabholtz; Pirkko-Liisa Kellokumpu-Lehtinen; Julie Taguchi; Federico Piacentini; Eva Ciruelos; Petri Bono; Mahmoud Ould-Kaci; Flavien Roux; Heikki Joensuu

doi:10.1016/S1470-2045(15)00373-3

Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial

Javier Cortes, Veronique Dieras, Jungsil Ro, Jerome Barriere, Thomas Bachelot, Sara Hurvitz, Emilie Le Rhun, Marc Espie, Sung-Bae Kim, Andreas Schneeweiss, Joo Hyuk Sohn, Jean-Marc Nabholtz, Pirkko-Liisa Kellokumpu-Lehtinen, Julie Taguchi, Federico Piacentini, Eva Ciruelos, Petri Bono, Mahmoud Ould-Kaci, Flavien Roux, Heikki Joensuu

Tutkimustuotos: Artikkelijulkaisu › Artikkeli › Tieteellinen › vertaisarvioitu

Alkuperäiskieli	englanti
Lehti	Lancet Oncology
Vuosikerta	16
Numero	16
Sivut	1700-1710
Sivumäärä	11
ISSN	1470-2045
DOI - pysyväislinkit	https://doi.org/10.1016/S1470-2045(15)00373-3
Tila	Julkaistu - joulukuuta 2015
OKM-julkaisutyyppi	A1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä, vertaisarvioitu

Tieteenalat

3122 Syöpätaudit

Pääsy asiakirjaan

10.1016/S1470-2045(15)00373-3

Siteeraa tätä

Cortes, J., Dieras, V., Ro, J., Barriere, J., Bachelot, T., Hurvitz, S., Le Rhun, E., Espie, M., Kim, S-B., Schneeweiss, A., Sohn, J. H., Nabholtz, J-M., Kellokumpu-Lehtinen, P-L., Taguchi, J., Piacentini, F., Ciruelos, E., Bono, P., Ould-Kaci, M., Roux, F., & Joensuu, H. (2015). Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial. Lancet Oncology, 16(16), 1700-1710. https://doi.org/10.1016/S1470-2045(15)00373-3

Cortes, Javier ; Dieras, Veronique ; Ro, Jungsil ; Barriere, Jerome ; Bachelot, Thomas ; Hurvitz, Sara ; Le Rhun, Emilie ; Espie, Marc ; Kim, Sung-Bae ; Schneeweiss, Andreas ; Sohn, Joo Hyuk ; Nabholtz, Jean-Marc ; Kellokumpu-Lehtinen, Pirkko-Liisa ; Taguchi, Julie ; Piacentini, Federico ; Ciruelos, Eva ; Bono, Petri ; Ould-Kaci, Mahmoud ; Roux, Flavien ; Joensuu, Heikki. / Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3) : a randomised, open-label, multicentre, phase 2 trial. Julkaisussa: Lancet Oncology. 2015 ; Vuosikerta 16, Nro 16. Sivut 1700-1710.

@article{ece440e655364d7f9f5f6b0fc4909725,

title = "Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial",

keywords = "ERBB FAMILY BLOCKER, BIBW 2992, SURVIVAL, CAPECITABINE, DISEASE, MUTATIONS, EFFICACY, BARRIER, 3122 Cancers",

author = "Javier Cortes and Veronique Dieras and Jungsil Ro and Jerome Barriere and Thomas Bachelot and Sara Hurvitz and {Le Rhun}, Emilie and Marc Espie and Sung-Bae Kim and Andreas Schneeweiss and Sohn, {Joo Hyuk} and Jean-Marc Nabholtz and Pirkko-Liisa Kellokumpu-Lehtinen and Julie Taguchi and Federico Piacentini and Eva Ciruelos and Petri Bono and Mahmoud Ould-Kaci and Flavien Roux and Heikki Joensuu",

year = "2015",

month = dec,

doi = "10.1016/S1470-2045(15)00373-3",

language = "English",

volume = "16",

pages = "1700--1710",

journal = "Lancet Oncology",

issn = "1470-2045",

publisher = "EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC",

number = "16",

}

Cortes, J, Dieras, V, Ro, J, Barriere, J, Bachelot, T, Hurvitz, S, Le Rhun, E, Espie, M, Kim, S-B, Schneeweiss, A, Sohn, JH, Nabholtz, J-M, Kellokumpu-Lehtinen, P-L, Taguchi, J, Piacentini, F, Ciruelos, E, Bono, P, Ould-Kaci, M, Roux, F & Joensuu, H 2015, 'Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial', Lancet Oncology, Vuosikerta 16, Nro 16, Sivut 1700-1710. https://doi.org/10.1016/S1470-2045(15)00373-3

Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3) : a randomised, open-label, multicentre, phase 2 trial. / Cortes, Javier; Dieras, Veronique; Ro, Jungsil; Barriere, Jerome; Bachelot, Thomas; Hurvitz, Sara; Le Rhun, Emilie; Espie, Marc; Kim, Sung-Bae; Schneeweiss, Andreas; Sohn, Joo Hyuk; Nabholtz, Jean-Marc; Kellokumpu-Lehtinen, Pirkko-Liisa; Taguchi, Julie; Piacentini, Federico; Ciruelos, Eva; Bono, Petri; Ould-Kaci, Mahmoud; Roux, Flavien; Joensuu, Heikki.

julkaisussa: Lancet Oncology, Vuosikerta 16, Nro 16, 12.2015, s. 1700-1710.

Tutkimustuotos: Artikkelijulkaisu › Artikkeli › Tieteellinen › vertaisarvioitu

TY - JOUR

T1 - Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3)

T2 - a randomised, open-label, multicentre, phase 2 trial

AU - Cortes, Javier

AU - Dieras, Veronique

AU - Ro, Jungsil

AU - Barriere, Jerome

AU - Bachelot, Thomas

AU - Hurvitz, Sara

AU - Le Rhun, Emilie

AU - Espie, Marc

AU - Kim, Sung-Bae

AU - Schneeweiss, Andreas

AU - Sohn, Joo Hyuk

AU - Nabholtz, Jean-Marc

AU - Kellokumpu-Lehtinen, Pirkko-Liisa

AU - Taguchi, Julie

AU - Piacentini, Federico

AU - Ciruelos, Eva

AU - Bono, Petri

AU - Ould-Kaci, Mahmoud

AU - Roux, Flavien

AU - Joensuu, Heikki

PY - 2015/12

Y1 - 2015/12

KW - ERBB FAMILY BLOCKER

KW - BIBW 2992

KW - SURVIVAL

KW - CAPECITABINE

KW - DISEASE

KW - MUTATIONS

KW - EFFICACY

KW - BARRIER

KW - 3122 Cancers

U2 - 10.1016/S1470-2045(15)00373-3

DO - 10.1016/S1470-2045(15)00373-3

M3 - Article

VL - 16

SP - 1700

EP - 1710

JO - Lancet Oncology

JF - Lancet Oncology

SN - 1470-2045

IS - 16

ER -

Cortes J, Dieras V, Ro J, Barriere J, Bachelot T, Hurvitz S et al. Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial. Lancet Oncology. 2015 joulu;16(16):1700-1710. https://doi.org/10.1016/S1470-2045(15)00373-3